Registered User Login
Asian Journal of Pharmaceutical Research
ISSN: 2231-5691(Online), 2231-5683(Print)
News & Conferences
Volume No. :
Issue No. :
ISSN Print :
ISSN Online :
Click to Login
Generic Vs. Brand Medicines: An Overview
Nikita R. Nikam
Rohan R. Vakhariya
Dr. C. S. Magdum
Nikita R. Nikam*, Rohan R. Vakhariya, Dr. C. S. Magdum
Rajarambapu College of Pharmacy, Kasegaon, Dist-Sangli, Tal-Walwa Maharashtra.
The Indian pharmaceutical industry is the winner in the form of the most affordable formula in the world. These "generic" formulations maintain a balance of public interest as a serious disease such as cancer, AIDS, etc. In December 2011, the Indian pharmaceutical market grew by 15.7%. By law, generic drugs can not be sold until the end of the patent name, which can take up to 10 years or more. Brand names have been defined in cases where current versions are not yet available. The generic pharmaceutical product that refers to the multi-source drug product is considered "substantially identical" or a bi-equivalent for the product of a (brand name) promoter. This document addresses various aspects of generic and branded drugs, their barriers and issues related to generic and brand medicine.
Generic, Pharmaceutical, Brand, Medicine.
Nikita R. Nikam, Rohan R. Vakhariya, Dr. C. S. Magdum. Generic Vs. Brand Medicines: An Overview. Asian J. Pharm. Res. 2019; 9(2): 109-115.
Visitor's No. :